Editorial Board About Us

Prostate cancer screening

All articles from this key word are listed below.

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Naoki Yoshimura Stacy Loeb J Curtis Nickel Claus G Roehrborn Michael K Brawer Arie S Belldegrun B Shuch F Pouliot Alan W Partin Dean G Assimos Ellen Shapiro Michael B Chancellor

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 12, Number 3 Meeting Reviews

Uro-Oncological Controversies in Euro-Oncology

Meeting Review

Bob Djavan Alexander Farr Elisabeth Eckersberger Helen Sadri Markus Margreiter Mike Harik Herbert Lepor

Highlights From the European Association of Urology Section of Oncological Urology, January 15-17, 2010, Vienna, Austria [Rev Urol. 2010;12(2/3):e125-e128 doi: 10.3909/riu0491]

Prostate cancer screening Bladder cancer Renal cancer Robotics Cancer mortality rates

Volume 16, Number 2 Meeting Reviews

Prostate Cancer Screening

Highlights From the 29th European Association of Urology Congress

[Rev Urol. 2014;16(2):90-91 doi: 10.3909/riu0616] © 2014 MedReviews®, LLC

Prostate cancer screening Prostate-specific antigen European Randomized Study of Screening for Prostate Cancer Rotterdam Prostate Cancer Risk Calculator

Volume 17, Number 3 Review Articles

Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Followi

Treatment Impact Assessment

Gregory C McMahon Gordon A Brown Kathleen F McGinley

On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)–based prostate cancer screening. Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24.1% increase in total visits, the 32 urologists in our practice completed 16.4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = .017) and 21.4% fewer prostate biopsies (42 fewer biopsies per month; P = .001) in the 2 years following the USPSTF grade D recommendation. [Rev Urol. 2015;17(3):171-177 doi: 10.3909/riu0696] © 2015 MedReviews®, LLC

Prostate cancer screening Prostate-specific antigen Prostate biopsies United States

Volume 20, Number 3 Original Research

Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation

Ann E Anderson Carl A Olsson Hugh J Lavery Deepak Kapoor

We report changes in the histopathology of prostate cancer diagnosed in a large urology group practice after the final United States Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen screening. All prostate biopsies performed from 2011 through 2015 in a large urology group practice were retrospectively reviewed; 2012 was excluded as a transition year. The changes in biopsy data in years following the USPSTF decision (2013-2015) were then compared with baseline (2011). A total of 10,944 biopsies were evaluated during the study period. Positive biopsy rates rose from 39.1% at baseline to 45.2% in 2015 (P < 0.01) with a marked shift toward more aggressive cancer throughout the study period. The absolute number of patients presenting with Gleason Grade Group 4 or 5 increased from 155/year at baseline to 231, 297, and 285 in 2013, 2014, and 2015, respectively (P < 0.05), unrelated to age or racial changes over time. Black men represented 16% of the cohort. Since the USPSTF recommendation against prostate cancer screening, trends toward a substantial upward grade migration and increased volume of cancers were noted in a cohort of nearly 11,000 patients in a real- world clinical practice. Additionally, continuing reductions in cancer detection in the United States may exacerbate these trends. [Rev Urol. 2018;20(3):125–130 doi: 10.3909/riu0815] © 2018 MedReviews®, LLC

Prostate cancer Prostate cancer screening Histopathology grade migration

Volume 20, Number 4 Review Articles

Focal Ablation of Prostate Cancer

Treatment Update

Herbert Lepor James Wysock Samuel Gold

The challenge to the urology community is to reduce the risks of screening and treatment by reducing the number of men undergoing unnecessary biopsy and whole-gland curative treatment of low-risk disease. There is compelling evidence that focal ablation of prostate cancer is truly minimally invasive and offers major functional advantages over whole-gland treatment. [Rev Urol. 2018;20(3):145–157 doi: 10.3909/riu0809] © 2019 MedReviews®, LLC

Prostate cancer screening High-intensity focused ultrasound Irreversible electroporation Focal ablation Prostate cancer treatment Vascular targeted photodynamic therapy

Volume 22, Number 4 Review Articles

Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical Practice

Management Update

Franklin Gaylis Kelly K Bree Paul Dato Christopher J Kane A Karim Kader Gerald L Andriole

Broad-based prostate-specific antigen (PSA) screening has saved lives but at a substantial human and financial cost. One way of mitigating this harm, while maintaining and possibly improving the benefit, is by focusing screening efforts on men at higher risk. With age, race, and family history as the only risk factors, many men lack any reliable data to inform their prostate cancer (PCa) screening decisions. Complexities including history of previous negative biopsies, interpretation of negative and/or equivocal mpMRI findings, and patient comorbidities further compound the already complicated decisions surrounding PCa screening and early detection. The authors present cases that provide real-world examples of how a single nucleotide polymorphism–based test can provide patients and providers with personalized PCa risk assessments and allow for development of improved risk-stratified screening regimens. [Rev Urol. 2020;22(4):152–158] © 2021 MedReviews®, LLC

Prostate cancer screening Risk stratification Somatic DNA test Germline DNA tests Single nucleotide polymorphism DNA test